Boston expands board, appoints tech specialist
This article was originally published in Clinica
Boston Scientific has appointed technology investor David Roux to its board, increasing the number of directors from 10 to 11, effective 1 January 2014. Mr Roux is a co-founder and director of Silver Lake, a private equity firm focused on technology investing. Before this, he was chair and CEO of troubled software developer Liberate Technologies, executive vice-president of its parent company and IT specialist Oracle, and senior vice-president of Lotus Development, which was acquired by computing giant IBM in 1995. The appointment comes as Boston attempts to turn the corner on a difficult few years, and some have speculated that Mr Roux could aid the firm’s M&A strategy in areas outside its core medical device expertise. This could include healthcare IT, which rival Medtronic made a move into earlier this year, buying telehealth specialist Cardiocom in August.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.